Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 10:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,450 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Age-Related Macular Degeneration
Interventions
Sirolimus, Standard of Care intravitreal injections of anti-VEGF
Drug
Lead sponsor
Maturi, Raj K., M.D., P.C.
Individual
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 21, 2017 · Synced May 21, 2026, 10:03 PM EDT
Terminated Phase 3 Interventional Results available
Conditions
Diabetic Retinopathy, Diabetic Macular Edema
Interventions
Pemafibrate, Placebo
Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
69
States / cities
Phoenix, Arizona • Campbell, California • Glendale, California + 52 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2020 · Synced May 21, 2026, 10:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available
Conditions
Normal Healthy Subjects With No Known Ocular Diseases, Glaucomatous Eyes, Eyes With Retinal Diseases
Interventions
Maestro, iVue
Device
Lead sponsor
Topcon Medical Systems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Pomona, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 27, 2022 · Synced May 21, 2026, 10:03 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers
Conditions
Macular Degeneration, Retinal Degeneration, Retinal Diseases, Eye Diseases
Interventions
Pistachio Group
Dietary Supplement
Lead sponsor
Tufts University
Other
Eligibility
40 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 8, 2023 · Synced May 21, 2026, 10:03 PM EDT
Conditions
Retinal Vasculitis
Interventions
aflibercept 2mg
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
290,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced May 21, 2026, 10:03 PM EDT
Conditions
Diabetic Retinopathy
Interventions
Octreotide Acetate in Microspheres, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 16, 2011 · Synced May 21, 2026, 10:03 PM EDT
Conditions
Radiation Retinopathy, Macular Edema
Interventions
Aflibercept every 2 months, Aflibercept monthly
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
St Louis, Missouri • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced May 21, 2026, 10:03 PM EDT
Conditions
Center-involved Diabetic Macular Edema (CI-DME)
Interventions
Diabetes Visual Function Study (DiVFuSS) softgels, canola oil placebo softgels, 2 per day
Dietary Supplement · Other
Lead sponsor
ZeaVision, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Olympia, Washington • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jul 1, 2020 · Synced May 21, 2026, 10:03 PM EDT
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Cidofovir, Probenecid
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
13 Years to 60 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
8
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced May 21, 2026, 10:03 PM EDT
Completed No phase listed Observational Accepts healthy volunteers
Conditions
Posterior Vitreous Detachment, Diabetic Retinopathy
Interventions
annular array ultrasound exam
Procedure
Lead sponsor
Columbia University
Other
Eligibility
60 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced May 21, 2026, 10:03 PM EDT
Conditions
Epiretinal Membrane
Interventions
27-gauge vitrectomy wound construction
Device
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 30, 2016 · Synced May 21, 2026, 10:03 PM EDT
Conditions
Nervous System, Diabetic Kidney Disease, Diabetes Mellitus, Type 2
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 100 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced May 21, 2026, 10:03 PM EDT
Conditions
Geographic Atrophy, Macular Degeneration
Interventions
Avacincaptad pegol (ACP)
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
65
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Encino, California + 59 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced May 21, 2026, 10:03 PM EDT
Conditions
Macular Degeneration
Interventions
Pegaptanib sodium
Drug
Lead sponsor
Eyetech Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 14, 2007 · Synced May 21, 2026, 10:03 PM EDT
Conditions
Retinal Neovascularization
Interventions
Not listed
Lead sponsor
Notal Vision Inc.
Industry
Eligibility
55 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
3
States / cities
Boston, Massachusetts • St Louis, Missouri • Florence, South Carolina
Source: ClinicalTrials.gov public record
Updated May 21, 2023 · Synced May 21, 2026, 10:03 PM EDT
Conditions
Cytomegalovirus Infections, Cytomegalovirus Retinitis, Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
16
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2008 · Synced May 21, 2026, 10:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers
Conditions
Diabetes
Interventions
Low Dose Sinemet CR, High Dose Sinemet CR, RETeval Electroretinogram (ERG) Testing, Contrast Sensitivity Testing, Visual Acuity Testing
Drug · Device · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced May 21, 2026, 10:03 PM EDT
Conditions
Retinal Vein Occlusion
Interventions
ANXV
Biological
Lead sponsor
Annexin Pharmaceuticals AB
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
7
States / cities
West Monroe, Louisiana • Hagerstown, Maryland • Tulsa, Oklahoma + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced May 21, 2026, 10:03 PM EDT
Conditions
Age-related Wet Macular Degeneration
Interventions
CG-P5 peptide, Placebo, Aflibercept Injection [Eylea]
Drug
Lead sponsor
Caregen Co. Ltd.
Industry
Eligibility
50 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
Manchester, Connecticut • Deerfield Beach, Florida • Augusta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced May 21, 2026, 10:03 PM EDT
Conditions
Cystoid Macular Edema
Interventions
Bromfenac (Xibrom), Refresh Plus
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 3, 2016 · Synced May 21, 2026, 10:03 PM EDT
Conditions
Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy
Interventions
Netarsudil Ophthalmic
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced May 21, 2026, 10:03 PM EDT
Conditions
Age Related Macular Degeneration (AMD)
Interventions
SPIN, Non-aerobic, stretching/balance intervention Control
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
65 Years to 89 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced May 21, 2026, 10:03 PM EDT
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Foscarnet sodium, Ganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
9
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2011 · Synced May 21, 2026, 10:03 PM EDT
Conditions
Macular Hole, Retinal Detachment
Interventions
Dorzolamide 2%-timolol 0.5% topical eyedrops
Drug
Lead sponsor
Mid Atlantic Retina
Other
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 3, 2019 · Synced May 21, 2026, 10:03 PM EDT